| Evan Fox, MD | |
|
300 Hebron Ave, Suite 107, Glastonbury, CT 06033 | |
| (860) 430-1150 | |
| (860) 430-1093 |
| Full Name | Evan Fox |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 36 Years |
| Location | 300 Hebron Ave, Glastonbury, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598837429 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 031192 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hartford Hospital | Hartford, CT | Hospital |
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.
As world leaders increasingly recognize the Zika virus as an international public health threat, the Center for Vaccine Development at the University of Maryland School of Medicine's Institute for Global Health has been chosen as one of three study sites in a human safety trial of a new Zika vaccine.
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.
› Verified 2 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.
As world leaders increasingly recognize the Zika virus as an international public health threat, the Center for Vaccine Development at the University of Maryland School of Medicine's Institute for Global Health has been chosen as one of three study sites in a human safety trial of a new Zika vaccine.
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.
› Verified 2 days ago
| Entity Name | Evan Fox Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457699712 PECOS PAC ID: 2365688728 Enrollment ID: O20130410000151 |
News Archive
Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.
As world leaders increasingly recognize the Zika virus as an international public health threat, the Center for Vaccine Development at the University of Maryland School of Medicine's Institute for Global Health has been chosen as one of three study sites in a human safety trial of a new Zika vaccine.
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Evan Fox, MD 300 Hebron Ave, Suite 107, Glastonbury, CT 06033 Ph: (860) 430-1150 | Evan Fox, MD 300 Hebron Ave, Suite 107, Glastonbury, CT 06033 Ph: (860) 430-1150 |
News Archive
Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.
As world leaders increasingly recognize the Zika virus as an international public health threat, the Center for Vaccine Development at the University of Maryland School of Medicine's Institute for Global Health has been chosen as one of three study sites in a human safety trial of a new Zika vaccine.
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.
› Verified 2 days ago
Dr. Audrey Garrett, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 55 Nye Rd, Suite 102, Glastonbury, CT 06033 Phone: 860-657-3056 Fax: 860-633-3517 | |
Richard Alan Miller, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 122 A Naubuc Avenue, Glastonbury, CT 06033 Phone: 860-657-3799 | |
Dr. Milind Kale, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 140 Glastonbury Blvd Ste 30, Glastonbury, CT 06033 Phone: 860-561-5453 Fax: 860-371-2527 | |
Dr. Claudia Mary Carbonari, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 39 Hampshire Dr, Glastonbury, CT 06033 Phone: 860-633-9522 Fax: 860-657-3667 | |
Mark Weremchuk, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 210 New London Tpke, Glastonbury, CT 06033 Phone: 860-633-1543 Fax: 860-659-9755 | |
Dr. Ian Richard Cameron, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 200 Oak St, Glastonbury, CT 06033 Phone: 860-657-3602 Fax: 860-657-4421 |